PMID- 16373773 OWN - NLM STAT- MEDLINE DCOM- 20060127 LR - 20131121 IS - 0033-8419 (Print) IS - 0033-8419 (Linking) VI - 238 IP - 1 DP - 2006 Jan TI - Depressive psychosis: clinical usefulness of MR spectroscopy data in predicting prognosis. PG - 248-55 AB - PURPOSE: To prospectively assess the usefulness of magnetic resonance (MR) spectroscopy data acquired before the initiation of medical therapy in predicting prognosis in patients with depressive psychosis. MATERIALS AND METHODS: All subjects gave written informed consent to an institutional committee for clinical research-approved study protocol. The clinical course after medication in 52 patients with depressive psychosis (age range, 52-78 years; 21 men, 31 women) was investigated. In all patients, MR spectroscopy was performed with a 1.5-T MR imaging unit before the initiation of medical therapy. Cerebrovascular lesions (CVLs), which appear as high-signal-intensity areas on T2-weighted MR images, were evaluated by using the Fazekas rating scale. Patients were classified into two groups on the basis of the ratio of N-acetylaspartate (NAA) to creatine and phosphocreatine (Cr): Patients in group A had an NAA/Cr ratio greater than 1.91, and patients in group B had an NAA/Cr ratio of 1.91 or less. To assess the response of the patients to medication, standard psychiatric tests--the Verbal Associative Fluency Test (VAFT), the Digit Symbol Test (DST), the Mini-Mental State Examination (MMSE), and the Hamilton Depression Rating Scale (HAM-D)--were administered before and after medical therapy was initiated. Mean test scores before and after medication were compared with paired t testing. P < .05 was considered to indicate a significant difference. RESULTS: There were 25 patients in group A and 27 in group B. In group A, the mean VAFT and DST scores increased and the mean HAM-D score decreased after medication. There was no significant difference in mean MMSE scores before and after medication (P = .945 for group A and P = .934 for group B). In group B, there were no significant differences in any of the psychiatric test scores before and after medication. The high-signal-intensity area score in group B was significantly higher than that in group A (P = .004). CONCLUSION: MR spectroscopy data obtained before the initiation of medical therapy were useful in predicting prognosis in patients with depressive psychosis; this suggests that the combined burden of all CVLs may affect the response to antidepressant medication. CI - RSNA, 2006. FAU - Kado, Hirotsugu AU - Kado H AD - Department of Radiology, Akita Research Institute for Brain and Blood Vessels, 6-10 Kubotamachi, Sensyu, Akita 010-0874, Japan. FAU - Kimura, Hirohiko AU - Kimura H FAU - Murata, Tetsuhito AU - Murata T FAU - Nagata, Ken AU - Nagata K FAU - Kanno, Iwao AU - Kanno I LA - eng PT - Journal Article PL - United States TA - Radiology JT - Radiology JID - 0401260 RN - 0 (Antidepressive Agents) RN - 30KYC7MIAI (Aspartic Acid) RN - 997-55-7 (N-acetylaspartate) RN - MU72812GK0 (Creatine) RN - N91BDP6H0X (Choline) SB - IM MH - Aged MH - Analysis of Variance MH - Antidepressive Agents/therapeutic use MH - Area Under Curve MH - Aspartic Acid/analogs & derivatives/metabolism MH - Choline/metabolism MH - Creatine/metabolism MH - Depressive Disorder/drug therapy/*metabolism MH - Female MH - Humans MH - Magnetic Resonance Spectroscopy/*methods MH - Male MH - Middle Aged MH - Predictive Value of Tests MH - Prognosis MH - Prospective Studies MH - Psychiatric Status Rating Scales EDAT- 2005/12/24 09:00 MHDA- 2006/01/28 09:00 CRDT- 2005/12/24 09:00 PHST- 2005/12/24 09:00 [pubmed] PHST- 2006/01/28 09:00 [medline] PHST- 2005/12/24 09:00 [entrez] AID - 238/1/248 [pii] AID - 10.1148/radiol.2381041375 [doi] PST - ppublish SO - Radiology. 2006 Jan;238(1):248-55. doi: 10.1148/radiol.2381041375.